Eli Lilly’s tirzepatide cuts risk of worsening heart failure in HFpEF, obese patients
Tirzepatide, currently marketed by Eli Lilly (NYSE:LLY) as Mounjaro and Zepbound for diabetes and weight loss, respectively, ...